SAB Biotherapeutics Files 8-K with Exhibits
Ticker: SABS · Form: 8-K · Filed: Apr 22, 2026 · CIK: 0001833214
Sentiment: neutral
Topics: disclosure, exhibits, filing
TL;DR
SAB Biotherapeutics dropped an 8-K with new exhibits on 4/22/26.
AI Summary
SAB Biotherapeutics, Inc. filed an 8-K on April 22, 2026, primarily for Regulation FD Disclosure and Financial Statements/Exhibits. The filing includes various documents such as an iXBRL 8-K, exhibits (EX-99.1, EX-99.2), graphics, and a PDF courtesy copy of EX-99.2. It also contains XBRL data files.
Why It Matters
This filing provides updated information and exhibits for SAB Biotherapeutics, Inc., which could contain material disclosures relevant to investors and stakeholders.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, not indicating any immediate operational or financial distress.
Key Numbers
- 0001193125-26-168569 — SEC Accession Number (Unique identifier for the filing)
Key Players & Entities
- SAB Biotherapeutics, Inc. (company) — Filer
- 0001833214 (company) — CIK Number
- 2026-04-22 (date) — Filing Date
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is for Regulation FD Disclosure and to provide Financial Statements and Exhibits, as indicated by Items 7.01 and 9.01.
When was this 8-K filing accepted by the SEC?
This 8-K filing was accepted by the SEC on April 22, 2026, at 08:13:57.
What are some of the document types included in this filing?
The filing includes an iXBRL 8-K, exhibits such as EX-99.1 and EX-99.2, graphic files, and a PDF courtesy copy of EX-99.2.
What is the CIK number for SAB Biotherapeutics, Inc.?
The CIK number for SAB Biotherapeutics, Inc. is 0001833214.
What is the SIC code for SAB Biotherapeutics, Inc.?
The SIC code for SAB Biotherapeutics, Inc. is 2836, which pertains to Biological Products (No Diagnostic Substances).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 22, 2026 regarding SAB Biotherapeutics, Inc. (SABS).